European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F10%3A00051539" target="_blank" >RIV/00216224:14110/10:00051539 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.3109/10428194.2010.516378" target="_blank" >http://dx.doi.org/10.3109/10428194.2010.516378</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3109/10428194.2010.516378" target="_blank" >10.3109/10428194.2010.516378</a>
Alternative languages
Result language
angličtina
Original language name
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
Original language description
Over the past two decades, not only treatment options, but also the diagnosis, staging, and risk assessment of multiple myeloma (MM), have undergone significant development, partially due to a deeper understanding of MM pathogenesis. High-dose chemotherapy with autologous stem cell transplant (SCT) still remains the standard therapy for younger patients, with novel agents now being included in both pre-transplant regimens and post-transplant consolidation/maintenance approaches. Similarly, novel agentsare also being incorporated into allogeneic SCT for selected patients. In the treatment of elderly patients with MM, novel agents have been successfully incorporated into less intensive regimens, including melphalan/prednisone, low-dose dexamethasone, and cyclophosphamide/dexamethasone. While second-generation proteasome inhibitors are currently being intensively investigated, the subcutaneous administration of bortezomib, being equivalent to the established i.v.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2010
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Leukemia & lymphoma
ISSN
1042-8194
e-ISSN
—
Volume of the periodical
51
Issue of the periodical within the volume
11
Country of publishing house
GB - UNITED KINGDOM
Number of pages
6
Pages from-to
2006-2011
UT code for WoS article
000284219400008
EID of the result in the Scopus database
—